iScience (Nov 2022)

Cancer cell intrinsic TIM-3 induces glioblastoma progression

  • Qing Guo,
  • Shuai Shen,
  • Gefei Guan,
  • Chen Zhu,
  • Cunyi Zou,
  • Jingyuan Cao,
  • Wen Cheng,
  • Xiaoyan Xu,
  • Juanhan Yu,
  • Zhiguo Lin,
  • Guoli Wang,
  • Ling Chen,
  • Peng Cheng,
  • Anhua Wu

Journal volume & issue
Vol. 25, no. 11
p. 105329

Abstract

Read online

Summary: Glioblastoma (GBM) is identified to share common signal pathways between glioma and immune cells. Here, we find that T cell immunoglobulin domain and mucin domain protein 3 (TIM-3) is one of the most common co-inhibitory immune checkpoints in GBM shared by tumor and non-tumor cells. Glioma cell-intrinsic TIM-3 is involved in not only regulating malignant behaviors of glioma cells but also inducing macrophage migration and transition to anti-inflammatory/pro-tumorigenic phenotype by a TIM-3/interleukin 6 (IL6) signal. In mechanism, as one of the major regulators of IL6, TIM-3 regulates its expression through activating NF-κB. Blocking this feedback loop by Tocilizumab, an IL6R inhibitor, inhibited the above effects and repressed the tumorigenicity of GBM in vivo. Our work identifies glioma cell-intrinsic functions of TIM-3/IL6 signal mediating the crosstalk feedback loop between glioma cells and tumor-associated macrophages (TAMs). Blocking this feedback loop may provide a novel therapeutic strategy for GBM.

Keywords